OTCMKTS:INVVY

Indivior Stock Forecast, Price & News

$9.33
+0.12 (+1.35 %)
(As of 04/15/2021 03:20 PM ET)
Add
Compare
Today's Range
$9.10
Now: $9.33
$9.33
50-Day Range
$8.21
MA: $8.79
$9.50
52-Week Range
$2.80
Now: $9.33
$40.00
Volume5,171 shs
Average Volume9,540 shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's products focuses on treating substance use disorder, opioid use disorder, and schizophrenia. It offers SUBLOCADE injection for subcutaneous use; SUBOXONE sublingual film; and PERSERIS for extended-release injectable suspension, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company is also involved in finance activities. It operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INVVY
Previous SymbolNASDAQ:INVVY
CUSIPN/A
CIKN/A
Phone804-379-1090
Employees796
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$785 million
Cash Flow$1.86 per share
Book Value$1.43 per share

Profitability

Net Income$134 million

Miscellaneous

Market Cap$1.37 billion
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Suboxone maker Indivior overhauls board
March 24, 2021 |  finance.yahoo.com
Is Indivior (LON:INDV) Using Too Much Debt? - Yahoo Finance
February 12, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.76 out of 5 stars

Medical Sector

1222nd out of 2,020 stocks

Pharmaceutical Preparations Industry

539th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$9.33
+0.12 (+1.35 %)
(As of 04/15/2021 03:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INVVY News and Ratings via Email

Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Indivior (OTCMKTS:INVVY) Frequently Asked Questions

Is Indivior a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Indivior stock.
View analyst ratings for Indivior
or view top-rated stocks.

What stocks does MarketBeat like better than Indivior?

Wall Street analysts have given Indivior a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Indivior wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Indivior's next earnings date?

Indivior is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Indivior
.

How has Indivior's stock been impacted by COVID-19 (Coronavirus)?

Indivior's stock was trading at $2.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INVVY stock has increased by 228.5% and is now trading at $9.33.
View which stocks have been most impacted by COVID-19
.

Who are Indivior's key executives?

Indivior's management team includes the following people:
  • Mr. Mark Crossley, CEO & Exec. Director
  • Mr. Ryan Preblick, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Jason Thompson, VP of Investor Relations
  • Ms. Cynthia Cetani, Chief Integrity & Compliance Officer
  • Mr. Jon Fogle, Chief HR Officer
  • Mr. Richard Simkin, Chief Commercial & Strategy Officer
  • Ms. Sue Learned, Sr. VP of Global Clinical Devel.
  • Hillel West, Chief Manufacturing & Supply Officer
  • Mr. Murali Gopal M.D., Chief Medical Officer

Who are some of Indivior's key competitors?

What is Indivior's stock symbol?

Indivior trades on the OTCMKTS under the ticker symbol "INVVY."

How do I buy shares of Indivior?

Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indivior's stock price today?

One share of INVVY stock can currently be purchased for approximately $9.33.

How much money does Indivior make?

Indivior has a market capitalization of $1.37 billion and generates $785 million in revenue each year. The company earns $134 million in net income (profit) each year or $1.15 on an earnings per share basis.

How many employees does Indivior have?

Indivior employs 796 workers across the globe.

What is Indivior's official website?

The official website for Indivior is www.indivior.com.

Where are Indivior's headquarters?

Indivior is headquartered at 10710 Midlothian Turnpike, North Chesterfield VA, 23235.

How can I contact Indivior?

Indivior's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.